Anda di halaman 1dari 5

The Lancet Home

Journals

Collections

Multimedia

Conferences

Information for

Submit a Paper

Share on mendeley Share on facebook Share on twitter Share on email More Sharing
Services

Login

Register

Register as a Guest

Register and Claim Your Subscription

Subscribe

Online First

Current Issue

All Issues

Special Issues

Multimedia

Information for Authors


Search Terms Search within Advanced Search

< Previous Article


Next Article >
Volume 383, No. 9918, p723735, 22 February 2014
Seminar

Malaria
Prof Nicholas J White, FRS
,
Prof Sasithon Pukrittayakamee, DPhil
,
Prof Tran Tinh Hien, MD
,
Prof M Abul Faiz, PhD
,
Prof Olugbenga A Mokuolu, FWACP
,
Prof Arjen M Dondorp, MD
Published Online: 15 August 2013

DOI: http://dx.doi.org/10.1016/S0140-6736(13)60024-0

Article Info
This article can be found in the following collections: Malaria; The Lancet Seminars

Summary

Full Text

Tables and Figures

References

Supplementary Material

Summary
Although global morbidity and mortality have decreased substantially, malaria, a parasite
infection of red blood cells, still kills roughly 2000 people per day, most of whom are
children in Africa. Two factors largely account for these decreases; increased deployment of
insecticide-treated bednets and increased availability of highly effective artemisinin
combination treatments. In large trials, parenteral artesunate (an artemisinin derivative)
reduced severe malaria mortality by 225% in Africa and 347% in Asia compared with
quinine, whereas adjunctive interventions have been uniformly unsuccessful. Rapid tests have
been an important addition to microscopy for malaria diagnosis. Chemopreventive strategies
have been increasingly deployed in Africa, notably intermittent sulfadoxinepyrimethamine
treatment in pregnancy, and monthly amodiaquinesulfadoxinepyrimethamine during the
rainy season months in children aged between 3 months and 5 years across the sub-Sahel.
Enthusiasm for malaria elimination has resurfaced. This ambitious but laudable goal faces
many challenges, including the worldwide economic downturn, difficulties in elimination of
vivax malaria, development of pyrethroid resistance in some anopheline mosquitoes, and the
emergence of artemisinin resistance in Plasmodium falciparum in southeast Asia. We review
the epidemiology, clinical features, pathology, prevention, and treatment of malaria.

This article is available free of charge.


Simply login to access the full article, or register for free if you do not yet have a username
and password.

Already registered? Please login.

Email/Username:

Password:

Remember me

Forgot password?

New to TheLancet.com?

Registration is free of charge and takes no more than two minutes. As a registered user,
youll be able to access selected articles for free, personalize and interact with the site.
Access this article on
ScienceDirect
Article Options

PDF (499 kB)

Download Images(.ppt)

Email Article

Add to My Reading List

Export Citation

Create Citation Alert

Cited by in Scopus (33)

Request Permissions
Linked Articles
Department of Error
Department of Error
The Lancet Journals

The Lancet

The Lancet Diabetes & Endocrinology

The Lancet Global Health

The Lancet Infectious Diseases

The Lancet Neurology

EBioMedicine

The Lancet Haematology

The Lancet HIV

The Lancet Oncology

The Lancet Psychiatry

The Lancet Respiratory Medicine

Information & Support

About Us

Information for Authors

Information for Readers

The Lancet Careers

Customer Service

Contact Us

Privacy Policy

Terms and Conditions


Subscription

Your Account

Subscription Options

Existing Print Subscribers

Copyright 2015 Elsevier Limited except certain content provided by third parties.
The Lancet is a registered trademark of Reed Elsevier Properties S.A., used under license.
The Lancet.com website is operated by Elsevier Inc. The content on this site is intended for
health professionals.
Cookies are set by this site. To decline them or learn more, visit our Cookies page.